-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Transcode Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2020 to Q3 2024.
- Transcode Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$2.17M, a 59.2% increase year-over-year.
- Transcode Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$14.7M, a 29.5% increase year-over-year.
- Transcode Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$19.4M, a 4.21% decline from 2022.
- Transcode Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$18.6M, a 203% decline from 2021.
- Transcode Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$6.15M, a 747% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)